Authors have no conflict of interest to declare.
Psoriasis, the liver, and the gastrointestinal tract
Version of Record online: 25 MAR 2010
© 2010 Wiley Periodicals, Inc.
Volume 23, Issue 2, pages 155–159, March/April 2010
How to Cite
Gisondi, P., Del Giglio, M., Cozzi, A. and Girolomoni, G. (2010), Psoriasis, the liver, and the gastrointestinal tract. Dermatologic Therapy, 23: 155–159. doi: 10.1111/j.1529-8019.2010.01310.x
This work was supported by the Ministero della Salute, and the Ministero dell'Istruzione, Università e Ricerca Scientifica (Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale (PRIN)).
- Issue online: 25 MAR 2010
- Version of Record online: 25 MAR 2010
- celiac disease;
- Crohn's disease;
- nonalcoholic fatty liver disease;
- ulcerative colitis
Psoriasis is a common chronic inflammatory, immune-mediated skin disease that is frequently associated with comorbidities including psoriatic arthropathy, chronic inflammatory bowel diseases, and cardio-metabolic disorders. In particular, nonalcoholic fatty liver disease affects about half of patients, Crohn's disease 0.5% and celiac disease 0.2–4.3% of patients with psoriasis. Some shared genetic traits as well as common inflammatory pathways may underlie these associations. The presence of comorbidities has important implications in the global approach to patients. In particular, traditional systemic antipsoriatic agents could negatively affect cardio-metabolic comorbidities as well as nonalcoholic fatty liver disease and may have important interactions with drugs commonly used by psoriasis patients. Moreover, patients with psoriasis should be encouraged to drastically correct their modifiable cardiovascular and liver risk factors, in particular obesity, alcohol consumption, and smoking habit, because this could positively affect both psoriasis and their life expectance.